secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125386
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track
--------------------------------------------------------------------

- Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.
- R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).
- Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.
- Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.
- Appointed Keith Lui as SVP of Commercial and Medical Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/0000950170-24-125386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/oric-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer